BERWYN, PA — Panavance Therapeutics Inc. has announced groundbreaking findings this week, demonstrating the potential of their investigational drug, misetionamide (GP-2250), to tackle various forms of cancer by directly inhibiting critical transcription factors c-MYC and NFkB. This promising data was presented at the Visceral Medicine Congress in Leipzig, Germany.
Misetionamide’s dual action marks a significant advancement in cancer treatment. C-MYC, often deregulated in cancer, is crucial for tumor metabolism and proliferation, while NFkB, a well-known tumor promoter, drives cell survival and blood vessel formation within tumors. By targeting both, misetionamide disrupts essential pathways that tumors use to grow and avoid destruction.
The preclinical studies bolster this potential, showing that misetionamide effectively reduces tumor size and prolongs survival in animal models across several cancer types, including ovarian, pancreatic, and breast cancers. The results also indicate that misetionamide enhances the efficacy of existing chemotherapy treatments.
“We are thrilled to highlight the unique mechanism of action of misetionamide, reflecting our commitment to advancing innovative cancer therapies,” said Greg Bosch, Chairman and CEO of Panavance. He emphasized the transformative potential of the drug by targeting c-MYC along with NFkB.
Hanns Moehler, PhD, Head, Pharmacology of Panavance, noted, “Since these two transcription factors work in concert to drive tumor growth and proliferation, misetionamide’s ability to directly inhibit both offers a powerful two-pronged approach to cancer treatment.” He further added, “The direct inhibition of both, c-MYC and NFkB, has long been an elusive goal in cancer drug therapy.”
As Panavance Therapeutics continues its research, these findings underscore misetionamide’s potential to become a pivotal player in the future of cancer treatment, offering a novel approach to combat the disease’s complexity.a
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.